The main goal of the trial is to estimate recurrence‑free survival, which measures the length of time a person lives without the cancer coming back after the first dose of the study drug. After the three infusions, participants will have regular check‑ups where doctors use imaging scans and a standard measurement system known as RECIST 1.1 to see if any tumors have grown or new ones have appeared. Terms such as “recurrence” refer to cancer returning, and “progression” means the disease getting worse. Safety will also be monitored, including watching for lung inflammation called pneumonitis, which can cause breathing difficulties. The study follows participants for several months after the last infusion to gather information on how long the cancer stays away and to assess any side effects.

Participants will receive the assigned tablet daily and the infusion every few weeks, with regular clinic visits for safety checks, blood tests and imaging scans such as CT scans to look for changes in tumor size. The study will continue until the disease gets worse, a participant stops treatment, or the trial ends. Researchers will record how long the cancer stays stable (progression‑free survival), overall survival, side effects, and quality‑of‑life questionnaires.

The main purpose of the trial is to keep participants who are still benefiting from the drug under medical supervision while safety is monitored. After joining, participants will continue to receive opnurasib on a regular schedule for as long as it remains helpful and tolerable. Visits will include simple check‑ups to record any side effects, any changes in dosage, and overall health. The study does not involve any additional invasive procedures beyond the usual care for this condition.

The main goal of the trial is to learn how safe the medicine is and how well patients can tolerate increasing doses. Participants will receive the drug in a series of treatment cycles that last about four weeks each, with the amount of medicine gradually increased in early groups to find the highest dose that can be given without unacceptable side effects.

During the study, patients will have regular check‑ups, blood tests, and scans to watch for any side effects and to see how the cancer responds. Any problems that arise will be recorded and managed by the medical team, and the study will continue until the predetermined number of treatment cycles is completed or if a participant chooses to stop early.

The study compares different treatment combinations in adults who have not yet received treatment for this cancer. Treatment is given in cycles, with medicine taken or infused over repeated visits. After the first part of treatment, the study continues with follow-up while treatment is ongoing, to watch for side effects and other health changes. Some people may receive different combinations as part of the study design.

Pemetrexed, cisplatin, and carboplatin are chemotherapy medicines, which are drugs used to kill cancer cells. Pembrolizumab is an immunotherapy medicine, which helps the body’s own defense system attack cancer cells. Intravenous means the medicine is given through a vein.

The study has more than one part. In the first part, small groups of people receive the drug combinations so that researchers can watch for side effects and choose a dose that can be used more widely. In the later part, more people receive the combinations to learn more about how the treatment works in the different cancer groups and to compare dose options in some groups. Because this is an open-label trial, everyone knows which treatment is being given.

During the trial, the treatment is given over time, and participants are followed closely while they are receiving it and for a period afterward. Doctors check for side effects, how well the cancer seems to respond, and how the body handles the drugs. The study includes people with several cancer types, and the treatment plan may differ depending on the cancer group and the study part.

The main purpose of this research is to determine if the combination of these three medications can help patients live longer compared to using docetaxel by itself. The study involves two groups of patients – one receiving all three medications, while the other group receives only docetaxel. The medications are given through different methods: tislelizumab and docetaxel are given through an intravenous infusion (into a vein), while N-803 is given as a subcutaneous injection (under the skin).

During the study, patients will receive treatment and have regular check-ups to monitor their health and how well the treatment is working. The treatment will continue as long as it appears to be helping and the side effects are manageable. Doctors will use special scanning techniques to measure if the tumors are shrinking and will track how long patients live after starting the treatment.

People in the study are assigned to one of the two medicines. The treatment is given over time as intravenous infusions, which means medicine is put directly into a vein. The study is double-blind, which means the people taking part and the study doctors do not know which treatment is being given. During the study, doctors follow how the cancer changes, watch for side effects, and check how well each medicine is tolerated.

People in the study receive the same cancer treatment, but pembrolizumab is started at different times of day. One group receives it in the morning, between 08:00 and 12:00, and the other group receives it in the afternoon, between 13:00 and 17:00. Treatment is then continued over several cycles, with regular medical checks during the study. The study looks at survival, cancer growth, side effects, and how treatment affects daily well-being and sleep.

The study is a randomized phase III trial, which means the treatment timing is assigned by chance and the treatment plan is being tested in a larger group of patients. The study is designed for adults with advanced lung cancer and will follow results over time to compare the two timing schedules.

The purpose of this study is to find out if TUB-030 is safe and well-tolerated by patients, to determine the right dose to use in future studies, and to see if the medicine has any effect on the cancer. The study will also look at how the body processes the medicine by measuring drug levels in the blood at different times. The study has different phases, starting with dose escalation where small groups of patients receive increasing doses to find the maximum safe dose, followed by a dose optimization phase where the most promising dose is tested in larger groups of patients with specific cancer types.

During the study, patients will receive TUB-030 in treatment cycles that last three weeks. The study team will regularly check for side effects, monitor how the cancer responds to treatment using imaging scans, and collect blood samples to measure drug levels and check for immune responses to the medicine. Patients will need to have tissue samples from their tumor available for testing to help understand how the treatment works. The study will continue until the cancer gets worse, side effects become too severe, or the patient and doctor decide to stop treatment.

The study will test a medication called cemiplimab (also known as LIBTAYO), which is given through an intravenous infusion. This medicine belongs to a group of drugs called immunotherapy, which helps the body’s immune system fight cancer cells. The purpose is to determine if giving cemiplimab after surgery can help prevent the cancer from returning, compared to patients who receive no additional treatment after surgery.

During the study, participants will either receive cemiplimab treatment or be observed without treatment. The medication will be given through an infusion into a vein every few weeks. The total treatment period may last up to 42 weeks. Doctors will monitor the participants’ health and check if the cancer returns during and after the treatment period.

The purpose of the study is to see how effective and safe these treatments are for patients with this type of lung cancer. Participants will receive either rilvegostomig or pembrolizumab, along with chemotherapy drugs such as carboplatin and paclitaxel. The study will monitor how long patients live and how long they remain free from cancer progression, which means the cancer does not get worse. The study will also look at other factors like the overall response to the treatment and any side effects experienced.

Participants will receive their treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will take place over several months, and participants will have regular check-ups to monitor their health and the effects of the treatment. The goal is to find out which combination of treatments works best for this type of lung cancer.

Participants may receive combinations of several medications, including the experimental drug rilvegostomig and the medication ramucirumab. Other medicines that may be part of the treatment plan include mycophenolate mofetil and infliximab. These medications are administered through different methods, such as oral pills taken by mouth or IV infusion, which is a process where medicine is delivered directly into a vein through a tube.

During the study, the way the body processes these drugs and how the immune system reacts to them will be monitored. The research will look at how well the treatments work by observing changes in the size of tumors and how long the cancer remains stable. Researchers will also track any adverse events, which are unwanted or harmful side effects that may occur during treatment.

The purpose of the study is to compare the effectiveness of different combinations of these treatments. Participants will receive either a combination of Dato-DXd and Pembrolizumab, with or without platinum-based chemotherapy, or a combination of Pembrolizumab, Pemetrexed, and platinum-based chemotherapy. The study aims to determine which combination works best in controlling the cancer and improving survival.

Participants in the study will receive their assigned treatments over a period of time, with regular monitoring to assess how the cancer responds to the treatment. The study will also involve the use of a placebo in some cases. The trial is designed to provide valuable information on the best treatment options for patients with this type of lung cancer, helping to improve future care and outcomes.

The treatment involves the intravenous administration of SGN-ALPV, meaning the medicine is delivered directly into a vein through a needle or tube. Participants in the study will receive the drug in different amounts to help researchers determine the highest dose that can be given safely without causing too many side effects. During the study, medical professionals will monitor how the body reacts to the medication and how much of the drug remains in the bloodstream over time.

The purpose of the study is to see if adding durvalumab to the usual treatment can help patients live longer without the cancer getting worse. The study will involve several medications, including carboplatin, cisplatin, paclitaxel, etoposide, and pemetrexed disodium, which are commonly used in chemotherapy. Another medication, infliximab, and mycophenolate mofetil, an immunosuppressive agent, are also part of the study. These treatments will be administered over a period of time, and patients will be monitored to assess the effectiveness and safety of the treatment.

Participants in the study will receive their treatment through intravenous infusions, which means the medication is given directly into a vein. The study will last for a maximum of 54 weeks, during which time patients will be closely observed by healthcare professionals. The goal is to determine if the combination of durvalumab and standard treatment can improve the outcomes for patients with this type of lung cancer.

The study is conducted using oral use, meaning the medication is taken by mouth in the form of a tablet. Participants will receive a single dose of 240 mg of the medication while in a fasted state, which means they have not eaten for a certain period before taking the drug. The study follows a crossover design, where participants receive different versions of the medication at different times to allow for direct comparison.

The purpose of this study is to find out if romiplostim can help maintain platelet counts high enough to allow patients to receive their full chemotherapy doses on time without delays or reductions. The study will compare romiplostim with placebo to measure its effectiveness. Participants entering the study must have a platelet count at or below a certain level and must have at least three more cycles of chemotherapy planned. The chemotherapy cycles are given every 21 or 28 days depending on the specific treatment plan.

During the study, participants will receive either romiplostim or placebo as an injection under the skin while continuing their regular chemotherapy treatment. The study medication will be given for a treatment period lasting up to 12 weeks. Doctors will monitor platelet counts, track whether chemotherapy doses need to be changed due to low platelets, and watch for any bleeding problems or other side effects. Participants will continue to be followed for safety monitoring for up to 36 months to check for any long-term effects.

The purpose of this study is to find out if telisotuzumab adizutecan is safe and works better than standard treatments for this type of lung cancer. The study will look at whether the treatment can shrink tumors, slow down cancer growth, and help people live longer. It will also measure how the treatment affects quality of life and physical functioning. The study has two parts: the first part will test the safety of the treatment and help determine the best dose to use, while the second part will compare how well the treatment works against standard care options.

During the study, participants will receive either telisotuzumab adizutecan or one of the standard treatment options. The medicine is given through an infusion into a vein over a period of time. Participants will have regular visits where doctors will check their health, take blood samples, and perform scans to see how the cancer is responding to treatment. The study will track how long it takes for the cancer to grow, how long people live, and whether tumors shrink or disappear. Participants may stay in the study for several months or longer, depending on how well the treatment works and whether they experience any problems.

During the study, patients will be divided into two groups. One group will receive cemiplimab alone, while the other group will receive cemiplimab together with chemotherapy. Before starting treatment, patients will have imaging scans performed to measure their cancer. These scans will be repeated at specific times during the study to see how the cancer is responding to treatment. Blood samples will also be collected to look at certain markers in the blood that might help doctors understand why some cancers grow quickly after treatment starts. The study looks specifically at a type of immune cell in the blood that may be connected to how the cancer responds to treatment.

The study will track several outcomes including how many patients experience rapid cancer growth, how many patients respond to treatment with their tumors shrinking, how long patients live without their cancer getting worse, and overall survival time. The study will also carefully monitor any side effects or unwanted reactions that patients may experience from the medications. Information gathered from imaging scans, blood tests, and tissue samples will help researchers better understand which patients might benefit most from receiving cemiplimab alone versus cemiplimab with chemotherapy.

The main purpose of this study is to compare how long people live when treated with the investigational medicine compared to docetaxel. The study will look at this in all people whose tumors have PD-L1 levels of at least one percent, and also specifically in those whose tumors have PD-L1 levels of fifty percent or higher. People taking part will be randomly assigned to receive either the investigational medicine or docetaxel. The study will also look at other things like how well the tumors respond to treatment, how long any response lasts, and what side effects occur with each treatment.

During the study, participants will receive their assigned treatment for up to sixty months. Those receiving the investigational medicine will get it at a dose based on their body weight, while those receiving docetaxel will get it at a dose based on their body surface area. The study team will regularly check how the cancer is responding to treatment and monitor for any side effects. Participants will also be asked about their quality of life and any symptoms they are experiencing. Blood samples will be taken from those receiving the investigational medicine to measure drug levels in the body and to check for immune responses to the medicine. Tumor tissue samples will also be collected for testing to help understand how the treatments work.

The purpose of this study is to compare how well MK-1084 combined with MK-3475A works compared to MK-3475A combined with chemotherapy in treating this type of lung cancer, particularly in people whose tumors show a certain marker called PD-L1. The study will look at how long participants live without their cancer getting worse, how long they live overall, whether their tumors shrink or disappear, and how long any response to treatment lasts. The study will also monitor what side effects occur and whether participants need to stop treatment because of these side effects.

During the study, participants will receive one of the two treatment combinations. They will have regular check-ups where doctors will examine them, take blood samples, and perform scans to see how the cancer is responding to treatment. Participants will also be asked to complete questionnaires about their quality of life, including questions about breathing difficulties, coughing, and chest pain. The doctors will track any health problems that occur during treatment and measure changes in symptoms and overall well-being throughout the study.

Patients in this study will receive zanidatamab on its own, without combining it with other cancer treatments. The medicine will be given regularly over a treatment period that can last up to 60 weeks. The doctors will check how the tumors respond to the treatment by doing regular scans and tests. Some patients in the study may have breast cancer or cancers of the stomach and food pipe area, and they may have received a specific type of HER2-targeted therapy before, which is a treatment that works against the HER2 protein. For other types of solid tumors, patients should not have had this type of treatment before.

During the study, doctors will monitor patients carefully to see if the treatment is working and to watch for any side effects. This includes checking heart function, blood tests to see how the liver and kidneys are working, and measuring the size of the tumors. Patients will also be asked about symptoms they experience using questionnaires. The study will look at how many patients see their tumors shrink, how long the treatment keeps working, and how long patients live. Blood samples will be taken to measure the amount of medicine in the body and to check if the body makes any reaction against the medicine.

The study aims to determine whether the combination of divarasib and pembrolizumab works better than the standard treatment combination in treating this type of lung cancer. The medications will be given through different routes – divarasib as tablets taken by mouth, while pembrolizumab, pemetrexed, carboplatin, and cisplatin are given through an intravenous infusion (through a vein).

During the study, doctors will monitor how the cancer responds to treatment and track any side effects that may occur. They will also assess how the treatment affects patients’ quality of life and symptoms related to their cancer, such as cough and breathing difficulties. The study will measure how long patients live without their cancer getting worse and their overall survival time.

The purpose of this research is to determine how well zoldonrasib works in treating patients with this specific type of lung cancer. The medication comes in tablet form and is taken by mouth. During the study, patients will receive zoldonrasib daily, with the maximum daily dose being 1200 mg. The treatment period may last up to 9 months.

Throughout the study, doctors will monitor patients’ health and track how their cancer responds to the treatment. They will check the size of tumors and watch for any changes in the patient’s condition. The study will also look at how long the treatment remains effective and track any side effects that may occur. Regular medical examinations and blood tests will be performed to ensure patient safety during the treatment period.

The purpose of this research is to determine if the combination of trastuzumab deruxtecan with pembrolizumab works better than the standard treatment in controlling the disease. The medications will be given through an intravenous infusion, which means they are delivered directly into a vein. Trastuzumab deruxtecan is a type of medication that specifically targets cancer cells with high HER2 levels, while pembrolizumab helps the body’s immune system fight cancer cells.

During the study, participants will be randomly assigned to receive either the new combination treatment or the standard treatment. Their cancer will be monitored regularly using imaging scans to check how well the treatment is working. The doctors will continue to check the participants’ health and watch for any side effects throughout the study period.

The purpose of this research is to determine if using THIO followed by cemiplimab helps patients with advanced NSCLC live longer compared to using standard chemotherapy alone. Both treatments are given through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein.

During the study, patients will be randomly assigned to receive either the THIO/cemiplimab combination or one of the standard chemotherapy medications. The treatment period may continue for up to 24 months. Throughout the study, doctors will monitor patients’ health and track how their cancer responds to the treatment. They will also watch for any side effects that may occur during the treatment period.

The purpose of this study is to determine how effective the combination of these medications is at eliminating cancer cells before surgery. The treatment is given in two phases – before surgery (called neoadjuvant treatment) and after surgery (called adjuvant treatment). Before surgery, patients receive both medications. After surgery, all patients receive zimberelimab, and some patients may also continue receiving sacituzumab govitecan.

During the study, patients will receive regular medical examinations and various tests to monitor their health and how well the treatment is working. The treatment period may last up to 54 weeks. Zimberelimab is given at doses up to 360 milligrams, while sacituzumab govitecan is given based on the patient’s body weight, up to 10 milligrams per kilogram of body weight.

The purpose of this study is to evaluate how well the combination of visugromab and nivolumab works with or without docetaxel compared to using docetaxel alone in patients who have already received one previous treatment for their cancer. Some patients will receive an inactive substance (placebo) instead of one of the study medications.

The treatment period may last up to 36 months. During the study, patients will receive regular medical examinations and various tests to monitor their health and how well the treatment is working. The medications being tested work in different ways to fight cancer: visugromab is an antibody that targets a specific protein, nivolumab helps the immune system fight cancer cells, and docetaxel is a chemotherapy drug that stops cancer cells from growing.

The study consists of two groups. In one group, patients will receive treatment after their cancer has been surgically removed. In the other group, patients will receive treatment before surgery. The medications will be given either by mouth or through an intravenous infusion. The treatment period may last up to 63 months, depending on the group.

The researchers will monitor how well the treatments work and track any side effects that may occur. They will measure how many patients have their cancer completely disappear after treatment and how long patients live without their cancer returning. The study will also look at overall survival and the safety of the treatment combinations.

The main goal of this research is to determine if sotorasib works better than docetaxel in treating this specific type of lung cancer. The study will measure how long the cancer can be controlled before it starts growing again and how long patients live with either treatment. During the study, doctors will also track changes in cancer-related symptoms such as breathing problems, coughing, and chest pain.

Throughout the study, patients will have regular medical check-ups and imaging tests to monitor their cancer. The research team will evaluate how well each treatment works by looking at changes in tumor size and watching for signs that the cancer is growing or spreading. They will also assess how the treatments affect patients’ daily activities and overall well-being.

The research involves different groups of patients who will receive different treatments. Some patients will take sotorasib alone, while others will receive it in combination with another cancer medication called pembrolizumab. The study includes patients with various types of solid tumors, including colorectal cancer. Different doses of the medication will be tested, including once-daily and twice-daily dosing schedules.

Throughout the study, doctors will monitor patients’ responses to treatment using various medical tests including computed tomography (CT) and magnetic resonance imaging (MRI) scans. They will track how the tumors respond to treatment and watch for any side effects. The study will also look at how the medication moves through the body and how it affects patients’ quality of life and cancer-related symptoms.

Participants in the study will receive these medications through intravenous infusion, which means the medicine is delivered directly into a vein. The research is divided into different stages to determine the safest and most effective dose of the medicine. During the first part, the focus is on how well the body tolerates the combination of drugs. The subsequent parts aim to see how well the treatments work to reduce the size or growth of the tumors.

One group will receive sotorasib combined with a platinum doublet, which refers to a combination of two drugs like carboplatin and pemetrexed. The other group will receive pembrolizumab along with the same platinum doublet. Other medications, such as folic acid, hydroxocobalamin, dexamethasone, and antiemetics, may be used to support the treatment and manage side effects. During the study, the time until the cancer grows or worsens and the total length of time patients live are monitored.

The purpose of the study is to characterize the pharmacokinetics, which describes how a drug moves through the body, specifically for the subcutaneous version of the medicine. Participants will be monitored to ensure the safety of this administration method and to see how much of the medicine stays in the bloodstream over time. During the course of the study, different doses may be used to determine the most appropriate amount for patients.

The purpose of the study is to determine how well this new drug works and to monitor its safety in people with this condition. During the study, participants will receive the medication, and their health will be closely monitored. This includes checking for any side effects and observing how the cancer responds to the treatment over time.

The treatments involve medications administered through an Intravenous line, which is a method of delivering medicine directly into a vein. One group receives the study drug PF-08634404 along with a combination of chemotherapy drugs, which may include Paclitaxel, Carboplatin, or Pemetrexed. Another group receives Pembrolizumab combined with these chemotherapy drugs. Some participants may also receive Paclitaxel Albumin-Bound or a Placebo involving Sodium Chloride. During the study, participants will be monitored to see how they respond to the medicines and to track their Overall Survival and Progression-Free Survival, which refers to the length of time during and after treatment that a person lives with the disease without it getting worse.

Several different medications are being studied, which may be given alone or in combination with other treatments. These include MK-1084, an oral tablet, as well as patritumab deruxtecan and sacituzumab tirumotecan, which are administered through intravenous infusion, a method where medicine is delivered directly into a vein. Other possible treatments include cetuximab. Some participants may also receive corticosteroids, which are medicines used to reduce inflammation.

During the study, participants will receive different combinations of these medications to see how they affect the cancer. The research will monitor how the body reacts to the treatments and whether the cancer shrinks or stops growing. The course of the study involves regular medical monitoring to track the effects of the drugs and any side effects that may occur.

Participants may receive several different medications. These include cetuximab, which is given through an intravenous infusion, a method of delivering medicine directly into a vein, and MK-1084, which is taken as a pill. Other medications being studied include pembrolizumab, also given by intravenous infusion. Some people may receive a combination of these new drugs, while others may receive standard treatments like carboplatin or pemetrexed.

During the study, different groups of participants will be assigned to receive different combinations of these medicines to see which ones work best. The process involves regular monitoring to see how the body reacts to the treatments and how the cancer changes over time.